Mesenchymal stem cell therapy for COVID-19 infection

COVID-19 emerged in December 2019 in Wuhan, China, spread worldwide rapidly, and caused millions of deaths in a short time. Many preclinical and clinical studies were performed to discover the most efficient therapy to reduce the mortality of COVID-19 patients. Among various approaches for preventing and treating COVID-19, mesenchymal stem cell (MSC) therapy can be regarded as a novel and efficient treatment for managing COVID-19 patients. In this review, we explain the pathogenesis of COVID-19 infection in humans and discuss the role of MSCs in suppressing the inflammation and cytokine storm produced by COVID-19. Then, we reviewed the clinical trial and systematic review studies that investigated the safety and efficacy of MSC therapy in the treatment of COVID-19 infection.

Automated summary

This review discusses the pathogenesis of COVID-19 infection and the role of MSCs in suppressing inflammation and cytokine storm. Additionally, it reviews clinical trials and systematic reviews on the safety and efficacy of MSC therapy in the treatment of COVID-19 infection.